Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 160

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 160
---
 positions. The 14 patent applications are pending
in the U. S., Taiwan, Europe, China, Hong Kong, Japan, Korea, India, Singapore, Canada, Russia, South Africa, Mexico and Australia. The
patents issuing from these pending applications will begin to expire in 2042, exclusive of possible patent term adjustments or extensions
or other forms of exclusivity.

In addition, we have 12 pending
patent applications, four PCT applications, and one provisional patent application, which relate to other potential approaches for our
products. Patents issuing from these applications will begin to expire in 2043, exclusive of possible patent term adjustments or extensions
or other forms of exclusivity.

In addition, we have 11 pending
patent applications, one PCT application, and one provisional patent application, which relate to other potential approaches for our products.
Patents issuing from these applications will begin to expire in 2043, exclusive of possible patent term adjustments or extensions or other
forms of exclusivity.

Grants Under the Innovation Law

Under the Encouragement of
Research, Development and Technological Innovation in the Industry Law 5744-1984, and the provisions of the applicable regulations, rules,
IIA directives and benefit tracks, (collectively, the “ Innovation Law”), research and development programs that meet specified
criteria and are approved by a committee of the IIA are eligible for grants. The grants awarded are typically up to 50% of the project’s
expenditures, as determined by the research committee and subject to the benefit track under which the grant was awarded. A company that
receives a grant from the IIA, or a grant recipient, is typically required to pay royalties to the IIA on income generated from products
incorporating know-how developed using such grants (including income derived from services associated with such products), until 100%
of the U. S. dollars-linked grant plus annual interest is repaid, based on the LIBOR interest rate, and since January 1, 2024 based on
the 12 month Term SOFR interest rate. The rate of royalties under the regular benefits tracks varies between 3% to 5% of the income generated
from the IIA-supported products. The obligation to pay royalties is contingent on actual income generated from such products and services.
In the absence of such income, no payment of such royalties is required.

The terms of the grants under
the Innovation Law also generally require that the products developed